Verified factor-similar pair

GRPM vs RZG

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

SMB
Similarity score
82
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • RZG has the higher backtested relative Sharpe (0.886 vs 0.862).
  • RZG is cheaper on dividend valuation (113 vs 184, where 100 is each fund's historical median).
  • GRPM has the stronger regression fit (adjusted R-squared 0.929 vs 0.910).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

GRPM

Invesco S&P MidCap 400 GARP ETF
SMB
Adj. R2
0.929
Rel. Sharpe
0.862
Mkt beta
1.02
AUM
US$464M
MER
0.35%
Valuation
184

RZG

Invesco S&P Smallcap 600 Pure Growth ETF
SMB
Adj. R2
0.910
Rel. Sharpe
0.886
Mkt beta
1.01
AUM
US$111M
MER
0.35%
Valuation
113

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
GRPM
+0.51
|t|
+10.7
RZG
+0.98
|t|
+18.2
diff -0.47
HML
GRPM
+0.22
|t|
+4.9
RZG
+0.06
|t|
+1.2
diff +0.16
RMW
GRPM
+0.16
|t|
+3.1
RZG
+0.13
|t|
+2.0
diff +0.03
CMA
GRPM
-0.02
|t|
-0.3
RZG
-0.08
|t|
-1.1
diff +0.06
UMD
GRPM
-0.07
|t|
-2.2
RZG
+0.00
|t|
+0.0
diff -0.07

Why This Pair Matches

Exposure level
77
Exposure shape
96
Mkt beta diff
0.01
Rel. Sharpe diff
0.024

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

GRPM fund page RZG fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.